Low Density Lipoprotein (LDL) News and Research

RSS

Data from ACCORD Lipid study: Abbott issues statement

Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies – glycemic control, blood pressure control and lipid control.

15 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.

11 Mar 2010

Controlling cholesterol using biologically active molecules isolated from algal infusion

Researchers at Wayne State University's Department of Nutrition and Food Science believe they've uncovered a unique method to control and regulate cholesterol using biologically active molecules isolated from ProAlgaZyme™ -- a proprietary algal infusion produced by Health Enhancement Products, Inc., of Scottsdale, Arizona.

11 Mar 2010

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

11 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.

10 Mar 2010

Study shows strawberries can provide immense health benefits

When it comes to eating healthy, most people know it's a good long-term choice, but what they may not know is that eating certain foods daily can provide immediate health benefits.

10 Mar 2010

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Atherotech Inc. today announced it will be presenting research in two poster sessions and exhibiting its VAP® Cholesterol Test in booth #1311 at the American College of Cardiology (ACC) 59th Annual Scientific Session Exposition. The annual meeting takes place March 14-16, 2010, at the Georgia World Congress Center in Atlanta.

9 Mar 2010

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.

8 Mar 2010

Exercising during weight regain can help improve metabolic health and disease risk

With the obesity rate rising for American adults and children, health concerns such as diabetes and cardiovascular disease are a frequent reality. Although obesity itself is a major risk factor for disease, most of the threat may be associated with a cluster of risk factors called the metabolic syndrome (MetS). Losing weight can improve health and reduce these risk factors, but many people have difficulty keeping the weight off.

3 Mar 2010

Study shows income is not a primary factor in medication adherence

Only 68 percent of corporate executives took their cholesterol lowering medication as prescribed by a doctor, a new study shows.

3 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That's the finding of a new study in the latest issue of the New England Journal of Medicine.

25 Feb 2010

Simple test to check personal cholesterol levels

CardioChek® test system is used by Americans and people in 100 countries around the world to test personal cholesterol levels. Simple, reliable and fast, CardioChek is manufactured by Indianapolis company Polymer Technology Systems, Inc., a leading global provider of point-of-care diagnostic products to the healthcare industry. On February 15th the CardioChek test system was featured on Lifetime Channel’s program, “The Balancing Act,” and will air again on February 22nd and March 15th.

23 Feb 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

Any new pressure in upper body can signal heart attack

Not everyone who suffers a heart attack clutches their chest and falls to the floor. "I woke up and felt like a pill was stuck in my throat," says Betsy, a 68-year-old patient from Upper Providence. "I was taking antibiotics at the time and really didn't think much of it," she adds. "So I tried drinking water and when the "stuck" feeling didn't go away after 45 minutes, I thought something might be wrong."

15 Feb 2010

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference “Advances in Molecular Mechanisms of Atherosclerosis” being held in Banff, Alberta, Canada. Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.

15 Feb 2010

Mediterranean diet beneficial to heart health: Study

In countries bordering the Mediterranean Sea, heart disease is less common than in the United States. Researchers believe that foods common to Greece and southern Italy are a major reason for this difference.

12 Feb 2010

Low Density Lipoprotein (LDL) News and Research

Data from ACCORD Lipid study: Abbott issues statement

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Controlling cholesterol using biologically active molecules isolated from algal infusion

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

Small study shows eprotirome decreases LDL cholesterol

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

Study shows strawberries can provide immense health benefits

Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Exercising during weight regain can help improve metabolic health and disease risk

Study shows income is not a primary factor in medication adherence

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Simple test to check personal cholesterol levels

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Any new pressure in upper body can signal heart attack

Idera Pharmaceuticals presents TLR antagonist preclinical hyperlipidemia data at Keystone Symposia conference

Mediterranean diet beneficial to heart health: Study

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News